Dublin, Ireland, May 8th, 2017 – DS Biopharma (DS), a clinical stage biopharmaceutical company, today announced the appointment of Professor Brendan Buckley as a non-executive director to the company’s Board.
Professor Buckley was the co-founder of Firecrest Clinical, a company which focused on improving the performance of clinical trial sites. A medical graduate of University College Cork (UCC) and a doctoral graduate in Biochemistry of Oxford University, Brendan has over 30 years’ experience in clinical research particularly in the areas of endocrinology, diabetes and pharmacology.
Brendan was previously Director of the European collaborative Centre for Clinical Trials in Rare Diseases at UCC, where he continues to hold an Honorary Clinical Professorship. He is also Adjunct Professor at University College Dublin and has published over 150 scientific papers.
He was a member of the Board of Directors of the Health Products Regulatory Authority of Ireland between 2004 and 2011 and held the position of chair of its statutory advisory committee for human medicines. Brendan was a member of the European Medicines Agency (EMA) Committee for Orphan Medicinal Products (COMP) from 2000-2003 and a member of the EMA Scientific Advisory Committee on Diabetes and Metabolism until 2011.
Brendan has directed a number of very large outcome trials in metabolic and cardiovascular disease. He is a member of the scientific advisory boards of a number of research charities as well as being a member of the Scientific Expert Group of UK Anti-Doping. Brendan was the Chief Medical Officer of ICON plc before retiring earlier this year.
“Professor Buckley brings a wealth of experience to the team and is a strong addition to the DS Board. I look forward to working with him in the coming years,” commented Dr. John Climax, Executive Chairman of DS.
About DS Biopharma
DS Biopharma, headquartered in Dublin, Ireland, is a privately held, clinical stage, pharmaceutical drug discovery and development company, which develops new medicines for unmet needs. The compounds under development are based on a novel bioactive lipid platform. These lipid molecules have been shown to be crucial to the pathways of several conditions including skin disorders such as atopic dermatitis (AD), rosacea and psoriasis.
DS Biopharma: firstname.lastname@example.org, +35312933590